Edward Jones has recently initiated Biomea Fusion Inc (BMEA) stock to Buy rating, as announced on October 9, 2024, according to Finviz. Earlier, on September 27, 2024, Truist had raised the stock from a Hold to Buy, setting a price target of $54. Rodman & Renshaw also raised Buy rating with a price target of $18. Additionally, CapitalOne initiated Overweight rating on August 29, 2024, with a target price of $25. Truist analysts, in their report published on June 11, 2024, also reduced Hold rating for Biomea Fusion Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Biomea Fusion Inc (BMEA) Stock Trading Recap
On Thursday, Biomea Fusion Inc (BMEA) stock saw a decline, ending the day at $9.37 which represents a decrease of $-0.97 or -9.38% from the prior close of $10.34. The stock opened at $10.46 and touched a low of $9.11 during the day, reaching a high of $10.8. The volume of shares traded was 2.34 million exceeding the average volume of 0.83 million.
BMEA Stock Performance and Moving Averages
In recent trading, Biomea Fusion Inc (BMEA) stock price has shown some volatility, fluctuating -18.94% over the last five trades and -7.50% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -21.46%, and it has gained 64.39% in the previous three months. Currently, BMEA is trading at -15.82%, -0.07%, and -12.63% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, BMEA, a Healthcare sector stock, is trading -58.80% below its 52-week high but remains 159.56% above its 52-week low. The Average True Range (ATR) (14 days) of 0.96 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Biomea Fusion Inc’s Profitability and Valuation Ratios
Biomea Fusion Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -21.46%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Biomea Fusion Inc’s market capitalization stands at $339.56 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 4.47, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 22.49% of Biomea Fusion Inc (BMEA)’s shares, while financial institutions hold 66.10%.
